JCRB1371 GS-3A4-HepG2

Cell information

Cell type:genetically-modified cells (View Pricing Information)

JCRB No.   JCRB1371 Cell Name   GS-3A4-HepG2
Profile   Human glutamine synthetase gene and drug-metabolizing CYP3A4 gene introduced Hep G2 cells. Other Name   
Animal   human Strain   
Genus   Homo Species   sapiens
Sex   M Age   15
Identity   available Tissue for Primary Cancer   liver
Case history   Liver cancer Metastasis   
Tissue Metastasized    Genetics   human glutamine synthetase and CYP3A4 introduced
Life Span   infinite Crisis PDL   
Morphology   epithelial-like Character   
Classify   transformed Established by   Omasa, T.
Registered by   Omasa, T. Regulation for Distribution   First submission should be under joint authorship with the developer.
Comment    Year   2009
Medium   RDF medium containing glucose (2.58 g/L), glutamine (333 mg/L), and 10% dialyzed fetal bovine serum. RDF medium is a 2:1:1 mixture of RPMI1640, DMEM, Ham's F12 without glucose and glutamine. Methods for Passages   Cells harvested after treatment with 0.25% trypsin.
Cell Number on Passage    Race   
CO2 Conc.   5% Tissue Sampling   Liver
Tissue Type   differentiated liver carcinoma

Detection of virus genome fragment by Real-time PCR
Detected DNA Virus tested Detected RNA Virus tested
CMV - parvoB19 - HCV - HTLV-1 -
EBV - HBV - HIV-1 - HTLV-2 -
HHV6 - HTLV-1 - HIV-2 - HAV -
HHV7 - HTLV-2 - -/negative.
nt/not tested.
(positive (+) does not immediately mean the production of infectious viral particles.)
BKV - HIV-1 -
JCV - HIV-2 -
ADV - HPV18 -

Cellosaurus(ExPASy) Cellosaurus (ExPASy) is developed by Amos Bairoch of the CALIPHO group at the SIB - Swiss Institute of Bioinformatics as part of the neXtProt project. Cellosaurus is a knowledge database of cell lines with various information summarized. CVCL_8560
Pubmed id:18846481Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Araki N,Tsuruoka S,Wang N,Hasegawa G,Yanagihara H,Ando H,Omasa T,Enosawa S,Nagai H,Fujimura A
Xenobiotica. 2008 Nov;38(11):1355-64
Pubmed id:17300000Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support.
Takahashi M,Sakurai M,Enosawa S,Omasa T,Tsuruoka S,Matsumura T
Cell Transplant. 2006;15(10):945-52
Pubmed id:16048486The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage.
Wang N,Tsuruoka S,Yamamoto H,Enosawa S,Omasa T,Sata N,Matsumura T,Nagai H,Fujimura A
Artif Organs. 2005 Aug;29(8):681-4
Pubmed id:15903254Construction and evaluation of drug-metabolizing cell line for bioartificial liver support system.
Omasa T,Kim K,Hiramatsu S,Katakura Y,Kishimoto M,Enosawa S,Ohtake H
Biotechnol Prog. 2005 Jan-Feb;21(1):161-7


LOT Information

Cell No.   JCRB1371 Cell Name   GS-3A4-HepG2
LOT No.   06302010 Lot Specification   distribution
Medium   RPMI1640(Invitrogen11875) :DMEM /F12(1/1) medium with10% dialized fetal bovine serum(Hyclone ARG26916) Temperature   37 C
Cell Density at Seeding   3.7-5.0x10^4 cells/sq.cm Methods for Passages   Cells were harvested after treatment with 0.25%trypsin(GIBCO)
Doubling Time   NT Cell Number in Vial (cells/1ml)   5.2x10^6
Viability at cell freezing (%)   99.0 Antibiotics Used   free
Passage Number   p4* PDL   NT
Sterility: MYCOPLASMA   - Sterility: BACTERIA   -
Sterility: FUNGI   - Isozyme Analysis   NT
Chromosome Mode   NT Chromosome Information   NT
Surface Antigen   NT DNA Profile (STR)   D5S818:11,12
Adhesion   Yes Exoteric Gene   NT
Medium for Freezing   Cell Banker BLC-1(Nihon Zenyaku Industries) CO2 Conc.   5 %
RFLP   NT Viability immediately after thawing (%)   
Additional information